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Abstract
Background: Cancer-associated fibroblasts, comprised of activated fibroblasts or myofibroblasts, are found in the stroma
surrounding solid tumors. These myofibroblasts promote invasion and metastasis of cancer cells. Mechanisms regulating
the activation of the fibroblasts and the initiation of invasive tumorigenesis are of great interest. Upregulation of the
cytoskeletal protein, palladin, has been detected in the stromal myofibroblasts surrounding many solid cancers and in
expression screens for genes involved in invasion. Using a pancreatic cancer model, we investigated the functional
consequence of overexpression of exogenous palladin in normal fibroblasts in vitro and its effect on the early stages of
tumor invasion.
Principal Findings: Palladin expression in stromal fibroblasts occurs very early in tumorigenesis. In vivo, concordant
expression of palladin and the myofibroblast marker, alpha smooth muscle actin (a-SMA), occurs early at the dysplastic
stages in peri-tumoral stroma and progressively increases in pancreatic tumorigenesis. In vitro introduction of exogenous
90 kD palladin into normal human dermal fibroblasts (HDFs) induces activation of stromal fibroblasts into myofibroblasts as
marked by induction of a-SMA and vimentin, and through the physical change of cell morphology. Moreover, palladin
expression in the fibroblasts enhances cellular migration, invasion through the extracellular matrix, and creation of tunnels
through which cancer cells can follow. The fibroblast invasion and creation of tunnels results from the development of
invadopodia-like cellular protrusions which express invadopodia proteins and proteolytic enzymes. Palladin expression in
fibroblasts is triggered by the co-culture of normal fibroblasts with k-ras-expressing epithelial cells.
Conclusions: Overall, palladin expression can impart myofibroblast properties, in turn promoting the invasive potential of
these peri-tumoral cells with invadopodia-driven degradation of extracellular matrix. Palladin expression in fibroblasts can
be triggered by k-ras expression in adjacent epithelial cells. This data supports a model whereby palladin-activated
fibroblasts facilitate stromal-dependent metastasis and outgrowth of tumorigenic epithelium.
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Introduction
Fibroblasts play a pivotal role in cancer invasion, metastasis,
and chemoresistance [1–7]. Cancer-associated fibroblasts are
myofibroblasts with contractile properties and alpha-smooth
muscle actin (a-SMA) staining is a hallmark of these cells [8].
The mechanism by which myofibroblasts enhance tumorigenesis is
underscored by three key studies that reveal: 1) cancer-associated
fibroblasts chaperone the cancer cells from the primary site into
the metastatic niche 2) blocking the activated fibroblasts before
tumor invasion initiates can prevent cancer; but stopping the
myofibroblasts after invasion has started is too late to prevent
cancer and 3) therapeutic treatment of pancreatic cancer that
reduces the cancer-associated fibroblasts is more effective in
prolonging survival than standard chemotherapy that targets only
the cancer cells [9–11].
The 90 kD isoform of palladin, an embryonic and cytoskeletal
protein vital to cell motility, is overexpressed in the cancer-
associated fibroblasts of a multitude of tumor types including
pancreas, breast, lung, kidney, and ovary but is expressed at lower
levels in normal stromal fibroblasts [12–15]. Palladin-expressing
fibroblasts are also found adjacent to cancer cells in lymph node
and liver metastases [12]. Dysregulation of palladin from cultured
cells results in aberrant actin organization, dysregulated cell
adhesion and motility, and gross disruption of cell morphology
[16–20]. Not surprisingly, palladin has been detected in expression
screens for invasion-specific genes in pancreatic and breast cancer
[21,22].
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and palladin in the setting of pancreatic cancer has come to light.
We have reported a highly penetrant, rare form of familial
pancreatic cancer (Family X) that is caused by a mutation in a
highly conserved region of 90 kD palladin. This mutation induces
cytoskeletal abnormalities and enhances migration when trans-
fected into cells that normally express minimal amounts of the
90 kD palladin isoform [19]. It was intriguing to find that the
palladin protein is overexpressed preferentially and ubiquitously in
the stromal compartment of pancreatic cancer rather than the
ductal epithelial cells [12,23].
The fundamental role of palladin in cell motility and the rising
awareness that activated fibroblasts can actually partner with
cancer cells to promote invasion and metastasis led to these
investigations. Herein, using pancreatic cancer as a model, we
unravel 1) when in neoplastic progression does palladin activate
fibroblasts, 2) the mechanism underlying the transition of the normal
fibroblast into an activated myofibroblast in the setting of cancer
and 3) how the myofibroblast could aid the cancer cells to escape.
In addition, we also explored the effects of an inherited mutated
90 kD palladin in the fibroblasts of a kindred predisposed to
pancreatic cancer (Family X or FX). Could a palladin-mutated
stromal fibroblast initiate cancer?
Results
Palladin expression in tumor-associated fibroblasts
occurs early in neoplastic progression and co-localizes
with a-SMA in human pancreatic cancer
Immunohistochemical (IHC) staining of myofibroblast marker,
a-SMA, and 90 kD palladin were performed concomitantly on
human tissue microarray blocks containing all histological stages of
human pancreatic cancer including precancerous lesions (Figure 1).
Normal pancreas lacked 90 kD palladin protein expression except
Figure 1. 90 kD palladin and a-SMA staining increase with progression of pancreatic tumorigenesis. A) Expression of palladin and a-
SMA was examined via IHC staining in pancreas specimens. Left: there is little to no staining in normal pancreas. Middle: expression increases in the
peri-tumoral fibroblasts of pancreatic dysplasia or PanIN 2. Right: expression is highest and most widespread in the fibroblasts surrounding pancreatic
cancer. B) Semi-quantitative readings provide IHC scores for tissue microarray staining of normal (NL), low-grade dysplasia (PanIN 2), high-grade
dysplasia (PanIN 3) and cancer (CA) by palladin and a-SMA. Staining of palladin or a-SMA was scored as 0 to 4. See also Table S1.
doi:10.1371/journal.pone.0030219.g001
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expression increased with neoplastic progression in the pre-
cancerous dysplastic lesions and the most striking feature was that
palladin staining was limited to the fibroblasts immediately
adjacent to the dysplastic ductal cells (Figure 1). In pancreatic
cancer, diffuse and strong palladin expression was observed
throughout the stroma, particularly in the area surrounding the
adenocarcinoma cells, in agreement with by previous reports
[12,23]. Expression of a-SMA in the cancer stroma closely
paralleled that of palladin as previously reported in renal cell
carcinoma [15]. Co-expression of a-SMA and palladin in the
fibroblasts surrounding the pre-cancerous lesions suggests that the
myofibroblast phenotype is activated early in neoplastic progres-
sion and becomes more widespread in cancer.
Palladin up-regulates a-SMA and activates fibroblasts to
become myofibroblasts
Based on the protein expression of palladin and a-SMA in peri-
tumoral fibroblasts, we sought to unravel the relationship between
these proteins. Palladin is markedly up-regulated during the
fibroblast-to-myofibroblast transition following treatment with
TGF-b1 [4] as is a-SMA [3]. In vascular smooth muscle cells,
palladin expression is required for a-SMA upregulation [24,25].
We wondered what regulatory effect these two myofibroblast-
associated proteins could have upon each other and the
myofibroblast phenotype (see data below). Transfection of the
90 kD isoform of wild-type (WT) or mutant P239S (FX) palladin
into normal human dermal fibroblasts (HDFs) up-regulates
myofibroblast markers, a-SMA and vimentin, and is sufficient to
trigger a myofibroblast phenotype following palladin induction. By
day 5 post-palladin transfection, a-SMA is significantly elevated
(27.4%62.8%) and even further increased by day 9 (79%615.7%)
(Figure 2). Transfection of palladin also resulted in upregulation of
11 myofibroblast contractile proteins reported by Malstrom et al.
[26] (including cofilin, vimentin, profilin, caldesmon, tropomyosin,
alpha enolase, beta actin, tubulin, Rho GTP dissociation inhibitor
1, calponin, and peptidyl-prolyl cis-trans isomerase A). This
proteomics analysis is discussed in greater detail later.
Palladin-activated fibroblasts develop a myofibroblast
phenotype
Introduction of 90 kD palladin (WT or FX) into HDF cells
(subsequently referred to as HDF-WT or HDF-FX) resulted in
alterations to the cellular morphology (Figure 3A). Under normal
growth conditions (with complete media), palladin-expressing
fibroblasts demonstrated a decrease in cell area, and an increase
in thin cellular protrusions with spike-like appendages compared
to the parental control cells. Cytoskeletal changes included both
lengthening and thickening/bundling of actin stress fibers
(Figure 3A). Thin cellular protrusions with spike-like appendages
are visible by electron microscopy in the palladin-expressing
fibroblasts (Figure 3B). Because many cancers form in an
inflammatory setting, and because cancer is considered the wound
that doesn’t heal [27], we also examined the palladin-expressing
fibroblasts after incubation in wounding media (conditioned media
from fibroblasts that were wounded with a pipette tip) to
Figure 2. Palladin expression is sufficient to induce normal human dermal fibroblasts (HDF) cells to become myofibroblasts. A) HDF
cells transfected with 90 kD palladin (WT or FX) or empty vector (EV) were examined for the myofibroblast markers a-SMA and vimentin via IF.
Red=a-SMA or vimentin; Blue=DAPI. B) HDF cells were treated as above in (A) and the expression of a-SMA was analyzed by RT-PCR. RNA was
harvested at the number of days indicated post-transfection. C) Expression of a-SMA was analyzed by RT-PCR. GAPDH was used as an internal loading
control and the relative expression of each sample versus TGF-b1 treated samples were plotted as fold induction 6 SD.
doi:10.1371/journal.pone.0030219.g002
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morphologic changes were markedly enhanced compared to the
empty-vector control fibroblasts (Figure 3C). The cells developed a
more fusiform or mesenchymal shape with long thin protrusions
compared to the empty-vector control fibroblasts (Figure 3C).
Palladin-expressing fibroblasts plus a stimulatory trigger
enhances invasive and migratory behavior
We next asked whether 90 kD palladin expression would affect
the migration and/or invasive capacity of fibroblasts. Migration
was tested using a transwell system where the cells can traverse
directly through pores from an upper chamber to a lower
chamber. Invasion was tested using a Matrigel-coated transwell.
Assay results were compared for incubation with complete media,
wounding media (conditioned media collected from confluent
HDF cells manually wounded with a pipet tip), or conditioned
media from Panc-1 epithelial cells. Previous studies have shown
that exposure of cells to wounding media, increases the migration
rate of epithelial cells [28]. In agreement with recent studies
showing anti-migratory effects of palladin expression in breast
cancer cells [29], in the absence of a wounding signal, palladin-
activated fibroblasts did not have enhanced migration or
invasion. However, a wounding signal dramatically increased
the migration and the invasive capacity of palladin-activated
fibroblasts (WT and FX) compared to empty vector control
(HDF-EV) (Figures 4A & 4B). While epidermal growth factor
(EGF) had a similar result on the cells as wounded media (data
not shown), incubation with conditioned media from pancreatic
cancer cells (Panc-1) did not enhance the invasiveness of palladin-
expressing cells (Figure 4B).
To verify whether palladin-expressing cells were capable of
degrading extracellular matrix, HDF-EV, HDF-WT, and HDF-
FX were grown on coverslips coated with fluorescently-labeled
gelatin. In the presence of wounding media, gelatin bundling was
observed and the gelatin surface was destroyed by the palladin-
expressing HDF-WT or HDF-FX cells, but not the normal
parental HDF-EV (Figure 4C). These destructive changes are
much more dramatic and widespread than would normally be
expected with invadopodia alone. We wondered if the palladin-
induced myofibroblasts had enhanced contractility that could
cause a ‘‘ripping’’ of the matrix. To answer this, we investigated
whether RhoA, a protein involved in cytoskeletal movement and
remodeling [30], was activated in the palladin-expressing cells and
found that RhoA levels were increased nearly 2-fold (Figure 4D).
This suggests that exogenous palladin expression promotes the
ability of myofibroblasts to both invade and destroy extracellular
matrix (Figure 4C). The invasive effects of wounding media and
EGF on palladin-expressing fibroblasts were not due to a
difference in proliferation rates (Figure 4E).
Previous investigators have suggested that tumor-associated
fibroblasts may lead cancer cells through the extracellular matrix
[31]. We queried whether the palladin-activated fibroblasts could
fit that paradigm. To examine this hypothesis, we performed 3D
invasion assays using slides developed by Bellbrook Labs
(Figure 5A). Two circular wells were connected by a central
straight channel of 1 mm61.8 mm. The channel was filled diluted
Figure 3. Morphological changes in palladin-expressing fibroblasts with and without exposure to wounding media. A) HDF
transfected with WT-palladin (WT) or FX-palladin (FX) were compared to empty vector (EV) using IF analysis of phalloidin stained cells grown in
complete media or wounding media. B) Phalloidin-stained HDF-WT cell protrusion was magnified by electron micrography (inset). C) HDF were
treated as above in (A) and cultured in wounding media. Phalloidin stained cells were analyzed by IF. Plots illustrate the relative surface area of cells
(top) and average length of protrusions (bottom). Data are representative of two independent experiments; values are expressed as the mean 6 SEM.
(t-test, *, p-value,0.05; **, p-value,0.01).
doi:10.1371/journal.pone.0030219.g003
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channel as an attractant and HDF or palladin-activated HDF were
loaded into the opposite well. Cell invasion into the matrigel-filled
channel was assessed at 12 hour intervals as fibroblasts moved
toward the attractant. In agreement with our transwell invasion
assays, palladin-activated fibroblasts invaded the channels more
quickly and migrated across the channel in significantly greater
numbers than control fibroblasts (Figure 5B). Even with extended
time, none of the HDF cells without palladin were able to cross the
channel. In contrast, the palladin-activated fibroblasts completely
crossed the 1 mm channel by 72 hours, creating tunnels that were
used by other activated fibroblasts that followed behind. The black
tunnels created by the palladin-activated fibroblasts are quite
clearly seen in the fluorescent-red channel of the 3D invasion
chamber (Figure 5C). In addition to the extensive tunneling
created by the palladin-activated fibroblasts toward the attractant,
the palladin-containing cells appeared to have better directional
movement towards the EGF attractant than the control cells
Figure 4. Palladin and a stimulatory trigger enhance HDF cell migration, invasion, and degradation of extracellular matrix. A)
Migration across a transwell was compared for HDF transfected with empty vector (EV), WT-palladin (WT), FX-palladin (FX) when exposed to normal
complete media or wounding media. Data shown is representative average 6 SEM of three independent experiments. (t-test, *, p-value,0.05) B)
Invasion across a matrigel-covered transwell was compared for HDF cells treated as above in (A) when exposed to complete media, wounding media,
or conditioned media from Panc-1 cells. Data shown is representative average 6 SEM of three independent experiments. (t-test, **, p-value,0.01) C)
HDF cells were transfected as above in (A) and plated onto coverslips coated with Texas Red-labeled gelatin. Representative images taken via IF are
shown. DAPI (blue) was used to visualize nuclei. D) Protein lysates from HDF cells transfected as above in (A) were tested for RhoA activity. Each
sample was run in triplicate in two independent experiments. Error bars indicate SD. (t-test, **, p-value,0.01) E) Proliferation assay of HDF cells
transfected as above in (A). Data indicates mean 6 SD for three independent wells.
doi:10.1371/journal.pone.0030219.g004
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where they started.
Panc-1 cells were added one day after the fibroblasts to evaluate
whether these epithelial cells would make use of the tunnels
previously created by the invading fibroblasts. Indeed, we were
able to identify Panc-1 cells following the palladin-activated
fibroblast cells through the tunnels (Figure 5D). Palladin-activated
fibroblasts had a direct influence on the behavior and appearance
of the Panc-1 pancreatic cancer epithelial cells. After co-culture of
Panc-1 and palladin-activated fibroblasts cells in the home well of
the 3D-invasion slides, the Panc-1 cancer cells migrated a much
further distance– some completely crossing the channel– while the
control palladin-free co-cultures revealed the Panc-1 cells barely
leaving the home well. In addition, in the presence of palladin-
activated fibroblasts, the Panc-1 cells developed an elongated
appearance (Figure 5D).
Palladin promotes invasion through the development of
invadopodia filled with matrix-destroying enzymes
To unravel the mechanism underlying the invasive capability
of the palladin-expressing fibroblasts, we examined the ‘‘feet’’ of
the palladin-activated fibroblasts, which had become more
prominent with the transition into myofibroblasts (Figure 3B).
HDF, transfected with and without palladin, were plated on
Figure 5. Palladin-activated fibroblasts lead Panc-1 cells through the extracellular matrix. A) Schematic of 3-D invasion assay showing
Texas Red labeled gelatin/matrigel mixture in the channel with 5 ng/ml EGF as an attractant in the left port and cells (HDF 6 palladin labeled with
QTracker 585 with or without Panc-1 labeled with QTracker655) seeded into the right port. Cell movement was evaluated as cells traversed the
channel (right to left directional movement) using confocal microscopy. B) Palladin-activated fibroblasts (green) invade further into the red matrigel
channel at all time points tested (24 and 72 hours) (Right panels) compared to HDF with EV (Left panels). Representative images taken with confocal
microscopy are shown. Bars indicate 100 mm. C) The yellow boxed region is shown at higher magnification to the right. top, Red matrigel is uniform
in the empty channel prior to invasion. middle, Palladin-activated fibroblasts (green fluorescence emission) created black tunnels (devoid of Texas Red
signal; see arrow) within the matrix. Bottom, Fibroblasts (white phalloidin stain) can move single file through the tunnels. Shown are representative
images taken with confocal microscopy. Bars indicate 50 mm. D) Panc-1 cells (pink; see arrowheads) follow palladin-activated fibroblasts (white)
through the channel while they do not follow the HDF-EV. Shown are representative images taken with confocal microscopy 72 hours after co-
culture. Channels were fixed and stained with DAPI.
doi:10.1371/journal.pone.0030219.g005
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transwell was too small for an entire cell to go through, it could
accommodate the podosomes, which had to first penetrate the
Matrigel layer (Figure 6A). The invadopodia/podosomes that
invaded through the matrix-covered pores were severed from the
cell body with a razor. Labeled quantitative proteomic analysis
was used to compare the proteins in the ‘‘feet’’ from palladin-
expressing fibroblasts relative to the ‘‘feet’’ from the normal
parental fibroblasts. Proteomic analysis revealed that over 200
proteins were dysregulated by $1.5 fold in the ‘‘feet’’ of
palladin-expressing fibroblasts relative to those of labeled control
cells. These dysregulated proteins including invadopodia pro-
teins [30,32,33], ras related and GTP binding proteins, and
proteolytic enzymes, (selected proteins, see Figure 6B; for
c o m p l e t el i s t ,s e eT a b l eS 2 ) .W ew e r ep a r t i c u l a r l yi n t e r e s t e di n
the invadopodia proteins, including cortactin, filamin A, beta-
integrin 1, vinculin, profilin, alpha-actinin, and cofilin [32,33].
Nearly half of the up-regulated proteins identified in our
Figure 6. Palladin-activated fibroblasts use invadopodia to degrade extracellular matrix. A) The underside of a 3 mm transwell shows
podosomes/invadopodia from an HDF-WT fibroblast that has invaded through the matrigel via IF. The ‘‘feet’’ were severed with a razor for proteomic
analysis. B) HDF cells transfected with GFP-empty vector (EV) or GFP-wildtype palladin (WT) were examined with phalloidin staining via IF. Palladin-
expressing fibroblasts have linear protrusions (arrowheads) filled with proteases and lysozymes such as Cathepsin D. Shown are representative
images. C) Proteomic analysis of the ‘‘feet’’ reveals overexpression of proteolytic enzymes, Rho activation proteins, and verifies the presence of
proteins previously identified in invadopodia. Shown are protein ratios from fibroblasts with WT or FX palladin relative to empty vector. See also
Table S2. D) HDF cells transfected with wildtype palladin were grown on matrigel covered coverslips. Erosive degraded tracks were detected via
electron microscopy. Bar indicates 1 mm.
doi:10.1371/journal.pone.0030219.g006
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components [34].
Quantitative proteomic analysis revealed up-regulation of the
palladin-binding protein, alpha-actinin which is another invado-
podia-related protein that has been associated with poor prognosis
in ovarian and pancreas [35,36]. The marked increase of alpha-
actinin in the stroma of the pancreatic cancer and pre-cancer was
validated by IHC (Figure S1). Validation of the increased
expression of selected invadopodia proteins –cofilin, cortactin,
and profilin–detected by the proteomics analysis was performed by
immunofluorescence and/or Western blot analysis (Figure S2).
In addition to invadopodia proteins, proteolytic enzymes were
also up-regulated in the ‘‘feet’’ of palladin-expressing fibroblasts
including ADAM22, aminopeptidases, and cathepsin D and B
(Figure 6C). Immunofluorescent staining of the cathepsin D,
confirmed that the protein is selectively overexpressed in the HDF-
FX and WT cells, but not in the parental fibroblasts with empty
vector (Figure 6C). Interestingly, cathepsin D has been shown to
stimulate fibroblast invasion and outgrowth and is reportedly
involved in paracrine interactions between tumor epithelium and
fibroblasts [37]. In addition to the expression of proteolytic and
matrix-remodeling proteins, destruction of matrigel by the
palladin-expressing HDF-WT cells is evident by electron micros-
copy (Figure 6D).
Palladin is up-regulated in fibroblasts by the adjacent k-
ras activated epithelial cells
Palladin is generally not mutated in sporadic pancreatic cancer
(data not shown) or in familial pancreatic cancers, other than
Family X [38–41]. Yet expression of 90 kD palladin has been
reported in the fibroblasts that surrounded pancreatic dysplastic or
cancerous ductal cells in 96% of pancreatic cancers, while the
fibroblasts that surround normal ductal cells do not [12,23]
(Figure 1). We hypothesized that paracrine signaling between the
cancerous epithelial cells and fibroblasts was likely responsible for
the up-regulation of palladin expression in the fibroblasts,
eventually turning them into tumor-associated myofibroblasts.
To test this hypothesis, normal human fibroblasts were co-cultured
in a transwell with immortalized normal pancreatic ductal cells
(HPDE cells) and with pancreatic ductal cancer cell lines which
have k-ras mutations (MiaPaCa and Panc-1). By day 5 of co-
culture, palladin was up-regulated in the fibroblasts adjacent to
both of the pancreatic cancer ductal cell lines (Figure 7A). By
comparison, normal fibroblasts that were adjacent to normal
pancreatic ductal cells did not express palladin (Figure 7B).
Next we wondered what the signal was from the cancer cells
that would up-regulate palladin in adjacent fibroblasts? In light of
our data showing the earliest time course for the up-regulation of
palladin in the peri-tumoral fibroblasts occurs at low-grade
dysplasia (known as PanIN 2 in the pancreas), we hypothesized
that palladin regulation must occur relatively early in tumorigen-
esis. K-ras mutations are ubiquitous in pancreatic cancer: present
in both the cancerous and pre-cancerous ductal cells [42]. Because
palladin over-expression is noted in the myofibroblasts immedi-
ately adjacent to the pre-cancerous ductal cells (Figure 1), we
speculated whether k-ras activation alone in ductal cells was
sufficient to cause up-regulation of 90 kD palladin in neighboring
normal fibroblasts. A similar co-culture experiment using the
transwells was devised with the normal fibroblasts in the lower
chamber; the upper chamber contained normal pancreatic ductal
epithelial cells (HPDE) transfected with wild-type k-ras, mutated k-
ras, or an empty-vector. Expression of either constituently
activated wild-type or mutated k-ras in HPDE cells was sufficient
to cause the up-regulation of palladin and a-SMA in the adjacent
normal fibroblasts (Figure 7B). Neither palladin nor a-SMA
Figure 7. Palladin is up-regulated in normal fibroblasts co-cultured with pancreatic cancer or normal epithelial cells containing K-
ras. A) HDF cells were examined for palladin expression via IF following co-culture with pancreatic cancer cell lines, MiaPaCa or Panc-1, for 7 days.
TGFb1 is shown as a positive control for up-regulating palladin in normal fibroblasts, no epithelial cells is the negative control. Scale bars indicate
20 mm. B) HDF cells were examined for a-SMA or palladin expression via IF following co-culture with normal pancreatic duct epithelial cells (HPDE)
that were mock transfected or transfected with wild-type or mutant K-ras. Scale bars indicate 20 mm.
doi:10.1371/journal.pone.0030219.g007
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atic ductal cells (HPDE) transfected with an empty vector.
Upregulation of a-SMA and palladin in fibroblasts by the
adjacent cancer cells is prevented by silencing of 90 kD
palladin
To determine whether the ras-induced transformation of
fibroblasts into myofibroblasts relied on a palladin dependent
pathway, we utilized shRNA to generate stable clones of HDF
with palladin knockdown and then measured palladin and a-SMA
production after 9 days of co-culture of the normal fibroblasts with
the pancreatic cancer cell line, Panc-1. We failed to detect a-SMA
expression by RT-PCR following co-culture of HDF cells stably
transfected with any of three distinct shRNA constructs targeting
90 kD palladin (Figure 8A; data not shown). However, upregula-
tion of a-SMA was observed upon co-culture with Panc-1 cells if
HDF cells were transfected with a control shRNA plasmid or in
untreated HDF cells. There was also a functional consequence to
silencing palladin in fibroblasts, as demonstrated by migration and
invasion assays (Figures 8B & 8C). Palladin silencing diminished
the functions previously associated with the myofibroblast
phenotype. Together these findings indicate that ductal cells
containing activated k-ras are sufficient to up-regulate palladin
expression in adjacent fibroblasts through paracrine signaling.
This in turn causes the fibroblast to transform into a myofibro-
blast. Complete silencing of palladin abrogates the process.
Mutated palladin (FX) confers some differences in protein
expression and behavior in fibroblasts compared to wild-
type palladin (WT)
For several reasons, we included in these experiments the study
of the P239S mutation in a highly conserved region of 90 kD
palladin that causes a rare form of autosomal dominant familial
pancreatic cancer. How could dysregulation of a cytoskeletal
protein in peri-tumoral fibroblasts predispose to such a lethal,
highly penetrant cancer? In these studies, we found that the FX
palladin expressing fibroblasts were significantly more invasive
than fibroblasts containing wild-type palladin. In addition,
quantitative proteome analysis detected expression of 88 proteins
that were unique to the HDF-FX (Table S2) and not detected in
HDF-WT. IHC of Family X pancreas reveals that low levels of
palladin are overexpressed in some of the normal appearing
fibroblasts adjacent to normal ducts, while this is not the case in
normal pancreas of donor controls (unpublished observations). Of
note, the Family X cancers all had k-ras mutations (data not
shown), as is seen in the sporadic form of the disease. Collectively,
these findings suggest that the FX palladin mutation confers a
distinct advantage from the myofibroblast side of the neoplastic
equation but that the fundamental genetic alterations, such as k-
ras mutation, are still required from the ductal cells for neoplastic
progression.
Discussion
Who would have thought that when looking at a pathology slide
of pancreatic or breast cancer, the vast field of fibroblasts
surrounding the cancer cells was anything but a scarring response
to the damaging cancer cells? The importance of stroma was
suggested decades ago, but only recently have biologists delved
deep into the role that cancer-associated fibroblasts play in all
stages of cancer including initiation, progression and metastasis
[1–4,6,7,43–45].
Physically, how can fibroblasts assist a cancer cell? Elegant
studies by Gaggioli have demonstrated that the myofibroblasts
create tunnels through the matrix– clearing a path that allows the
cancer cells to follow behind, much as cars could follow a
snowplow [31,46]. Through the work presented here, the
mechanism underlying myofibroblast-led tumor invasion becomes
clearer. Palladin activates fibroblasts inducing them to become
Figure 8. Silencing of Palladin abrogates the myofibroblast phenotype and function. A) HDF cells were stably transfected with control
shRNA (C) or shRNA against 90 kD palladin (Pal shRNA). a-SMA expression following co-culture with Panc-1 cells was analyzed via RT-PCR. Analysis of
untreated HDF (U) is shown for comparison. The first lane is a non-template negative control; GAPDH is shown as an internal loading control. Shown
is data from one representative shRNA stable clone (of three independent shRNA constructs tested). B) Invasion across a matrigel coated transwell
was compared for HDF transfected as in (A). Shown is the mean 6SD. Shown is data from one representative shRNA stable clone (of three shRNA
constructs tested). C) HDF cells as in (A) were grown to confluence on coverslips and wounded with scratch test. Migration was assessed via IF
24 hours after wounding. At least 3 observations for each condition were analyzed. Blue=DAPI. Shown is data from one representative shRNA stable
clone (of three shRNA constructs tested).
doi:10.1371/journal.pone.0030219.g008
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phenotype and proteomic profile compared to normal fibroblasts.
The cells develop streamlined body shapes and innumerable
invadopodia filled with destructive enzymes. With a wounding
signal, the activated fibroblasts become invasive; their increased
contractility allows them to literally rip through tissue while at the
same time, the developed invadopodia destroy the matrix. While
we have not identified which factor(s) in the wounding media
contributes to the enhanced migration and invasive capacities
observed here, this would be an area for future investigation.
From our invasion assays, we observed that palladin-activated
fibroblasts could invade through matrigel a distance approximately
600 mm within a 24 hour period (Figure 5). If the average human
pancreas is 15 cm in length, this data would suggest that these
activated cells could potentially migrate the entire length of the
pancreas within 250 days, and could travel to the lymphatic or blood
vessels in significantly less time. These tunnels could then also be
utilized by tumorigenic epithelium or other cell types. Interestingly,
without a wounding signal, the myofibroblasts are less motile than a
normal fibroblast. Recent studies in mice have demonstrated that
PDAC induction is dependent upon both the k-ras oncogene and a
STAT3-dependent inflammatory component, such as chronic
pancreatitis [47,48]. These collective observations might allude to
why a cancer could remain dormant versus invasive over time:
without a trigger/signal propelling forth the activated and invasive
fibroblasts, the cancer cells are significantly less invasive. Concep-
tually, such a trigger-signal could be a growth factor or chemokines,
such as EGF, or wounding media, as we show in our studies.
Activation of palladin early in tumorigenesis
Using pancreatic cancer as a model, we determined that tumor-
associated fibroblasts express palladin very early in tumorigenesis,
when ductal cells have low-grade dysplasia, as demonstrated
previously in a mouse model of pancreatic cancer [12]. Moreover,
the number of palladin-expressing fibroblasts expands with
neoplastic progression to involve all of the stromal fibroblasts by
the time that cancer forms. We demonstrate that k-ras activation
or mutation in the epithelial cells is sufficient to induce up-
regulation of palladin in the adjacent normal fibroblasts and
transform them into myofibroblasts within 5 days. Studies by
Logsdon have shown that the degree of k-ras expression in an
epithelial cell positively correlates with the level of dysplasia of that
epithelial cell [49]. One could hypothesize that as k-ras signaling is
amplified with neoplastic progression of the epithelial cell; palladin
expression is augmented in fibroblasts to reach an exuberant level
by the time that cancer develops. One drives the other. Our IHC
studies demonstrating that palladin expression in the stroma
increases with advancing tumorigenesis would certainly fit with
this hypothesis. Future studies could help unravel the biochemistry
that underlies the ras/palladin relationship.
Initiation of cancer
Can a fibroblast initiate a cancer? Some data suggests this is
possible. Cancer-associated fibroblasts that are mixed with non-
tumorigenic prostate epithelial cells can induce tumorigenesis in
mouse models [50]. Carcinogen-treated mammary gland stroma,
when mixed with unexposed, normal mammary epithelial cells,
results in adenocarcinomas in mice [51]. Endometrial stromal cells
mutated with APC acquire a myofibroblast phenotype and the
stromal cells alone are sufficient to induce endometrial cancer in
an engineered mouse model [52]. Conversely, ‘‘good’’ fibroblasts
can help prevent tumorigenesis in mouse mammary tumor and
liver cancer models [51,53]; cancer cells that are placed in a
normal embryonic microenvironment can be reprogrammed to
behave normally [54]. As the tumor-modulating role of stromal
cells has been uncovered, investigators have looked for mutational
defects in the cancer-associated fibroblasts to account for fibroblast
cancer-promoting behavior [55]. Our data suggests at least one
simple process to change the behavior of a stromal fibroblast: the
paracrine signaling between an epithelial cell and its adjacent
fibroblast. Activation of k-ras in an epithelial cell is sufficient to
transform a fibroblast into a myofibroblast through palladin
expression. One could posit that a mutation of k-ras in an epithelial
cell would insure that k-ras is in an activated state long-term,
providing a continuous signal to the adjacent fibroblast. However,
in order to initiate invasion, it appears that the equation requires
an activated palladin-expressing fibroblast plus injury, as discussed
above. Perhaps this could explain why chronic injury in an organ,
such as inflammation, leads to an increased risk of cancer—in such
a setting, activated fibroblasts could more easily become deadly
partners of cancer cells because the injury is ever-present.
What can Family X, who inherited a mutation in the highly
conserved region of 90 kD palladin, tell us about this paradigm of
cancer initiation? It appears that the palladin mutation confers a
super-invasive behavior of the fibroblasts, but a k-ras mutation is
still required. This might explain why family members don’t
acquire cancer in childhood but rather in mid-adulthood at ages
30–50. It may take decades of time to acquire k-ras mutations in
the pancreas and to generate an injury signal such as could be
caused by smoking, excess alcohol, or fatty oxidation. The
susceptibility of the family members to pancreatic cancer thus
would require all 3 elements for pancreatic cancer: k-ras mutation,
injury, and palladin-activated fibroblasts; but in the case of Family
X, it takes less to initiate or promote a cancer as they already
possess one of the required elements: the easily primed, palladin-
mutated fibroblasts. In this setting, it seems unlikely that any
dysplasia could remain dormant. Without the ‘‘good’’ fibroblast
for protection, any spark could ignite the cancer. Future studies
could help determine whether an activated fibroblast can confer
mutational susceptibility to an adjacent epithelial cell.
Thetumorstromaisanominouspartnerofthetumorcells:afield
of activated myofibroblasts enhances invasiveness and metastases of
the surrounded cancer cells. In this study, we demonstrate that
introduction of wild-type or mutated (FX) palladin in a normal
fibroblast cell line is sufficient to transform the cell into
myofibroblasts as evidenced by up-regulation of a-SMA and
vimentin. Palladin alters the cell shape into spindle-shaped cells
with numerous invadopodia, and alters cell function by enhancing
the capacity for migration and invasion. In pancreatic cancer,
palladin expression occurs early in neoplastic progression and
expands from peri-ductal fibroblasts adjacent to dysplasia to
ubiquitous expression throughout the cancer stroma. Fibroblast
expression of palladin is induced by k-ras activation in the adjacent
ductal cells and the transition of the fibroblast to myofibroblast is
palladin-dependent. While palladin expression is sufficient and
necessary to induce phenotypic myofibroblast changes, a wounding
signal is required to launch the primed cell into an invasive, leading
partner for cancer cells. Thus, the large number of myofibroblasts
that make up what appears to be static ‘‘scar tissue’’ in some cancers
maybe,onthecontrary,inanactivestate ofmovementthat extends
beyond the organ of origin. Palladin appears to play a centralrolein
the arousal of the fibroblasts in tumorigenesis.
Methods
Specimens
Pancreatic tissue specimens were collected in accordance with
approved Human Subject’s guidelines at the University of
Palladin Activates Cancer-Associated Stroma
PLoS ONE | www.plosone.org 10 January 2012 | Volume 7 | Issue 1 | e30219Washington and Virginia Mason Hospital in Seattle, and the
Cleveland Clinic Foundation in Cleveland. All of the specimens
were obtained from surgical resections intra-operatively, immedi-
ately processed for paraffin embedding.
Cell culture and SILAC labeling
Human dermal fibroblasts (HDF), Panc-1 and MiaPaCa cells
were maintained in complete DMEM supplemented with 10%
fetal bovine serum and 0.01% penecillin-streptomycin in a
humidified incubator at 37uC with 5% CO2. The normal human
pancreatic ductal epithelial cell line (HPDE) was obtained from
Dr. Ming-Sound Tsao (University of Toronto, Ontario, Canada).
WT and FX palladin (90 kD isoform) constructs were described
[19]. Wounding conditioned media was prepared by manually
wounding confluent HDF cells and incubating with fresh complete
media for 16–18 hours. HDF cells were grown in modified
DMEM with
13C6-lysine and
13C6-arginine (Thermo Scientific) for
SILAC labeling. Cells were transfected as previously described
[56]. 24 hours post-transfection, cells were flow sorted for GFP
signal on a Cytopeia Influx Flow Cytometer or a BD FACS Aria
II. Brightfield images were taken using the 106 objective on a
Leica DMLB microscope equipped with a Spot Insight camera
using Spot Advanced software.
Co-culture and palladin knockdown
HDFs were grown in 6 well dishes and transwells (Corning)
containing HPDE, Panc-1, or MiaPaCa cells were placed atop
HDF cells (day 1). Cells were fed every 2–3 days with complete
DMEM and passaged as needed. shRNA plasmids were purchased
from Qiagen and transfected into competent JM109 cells
(Promega). Transformants were selected with ampicillin and
DNA isolated using the Qiagen Endo-Free Plasmid Kit as per
manufacturer’s instructions. DNA was digested with ScaI (New
England Biolabs) overnight at 37uC and cleaned up using the
MinElute Clean Up Kit (Qiagen) as per manufacturer’s instruc-
tions. HDF cells were transfected with linearized ScaI plasmids
using the Attractene Reagent (Qiagen). Cells were selected with
10 mg/ml puromycin (Invitrogen) for one week; media was
changed every 2–3 days. Stable transfectants were then selected
with 100 mg/ml puromycin treatment for 6 weeks with media
change every 2–3 days.
RT-PCR
Total RNA was isolated from cell pellets using the RNeasy Mini
kit (Qiagen) as per manufacturer’s instructions. 50 ng RNA was
used for first strand cDNA synthesis using the SuperScript III First
Strand Synthesis System (Invitrogen). 2 ng of cDNA was used for
RT-PCR using the FastStart Taq Kit (Roche). Primer sequences
and conditions were as described for a-SMA [57]. Palladin was
amplified using the following primers: forward, ctgcccaagggtgtcac;
reverse, ctttggctttggatttccag. Gels were analyzed using ImageJ to
determine relative band intensities.
Tissue microarray construction
Tissue microarrays were constructed from representative
pathologic or normal tissues from paraffin-embedded formalin
or Hollande’s-fixed samples. Histology of cores was independently
verified by pathologists (MPB and JC). For palladin, sections
included 47 different cases of sporadic pancreatic ductal
adenocarcinoma 20 PanINs, and 91 different cases of normal
pancreas (including sections from normal, pancreatitis, and
normal sections adjacent to adenocarcinoma). Triplicate 1.5 mm
diameter cores of each tissue type were embedded into a
systematic grid using a tissue arrayer (Beecher Instruments) as
previously described [58].
IHC
Immunohistochemical staining for smooth muscle actin was
performed on 4 mm paraffin-fixed sections with the Benchmark
XT, an automated immunostainer from Ventana Medical Systems
(VMS), Tucson, AZ, USA. Briefly, the slides were processed for
antigen retrieval using microwave heating in a citrate buffer,
followed by primary antibody incubation using the 1E6 monoclo-
nal palladin antibody [19] at a titer of 1:5000 or a mouse
monoclonal antibody for smooth muscle actin (Dako) at a dilution
of 1:50. The specific protein-antibody complexes were located
using a biotin/streptavidin-HRP/(DAB) detection kit (iView DAB
Detection). Scoring guidelines are outlined in Table S1.
Fluorescence microscopy
For cell morphology experiments, cells were grown on
coverslips and stained with Texas Red phalloidin (Invitrogen)
diluted 1:1000. For immunofluorescence, HDF cells were grown
on coverslips, fixed with4% paraformaldehyde, and permeabo-
lized briefly with 0.2% Triton X-100. Antibodies against the
following proteins were used at the indicated dilutions: Texas Red
phalloidin (Invitrogen) 1:1000; a-SMA rabbit 1A4 (Abcam) 1:400;
palladin (Proteintech) 1:1000; palladin (Novus Biologicals) 1:1000;
cortactin (Abcam) 1:500; nestin (Millipore) 1:200;profilin (BD
Biosciences) 1:400; cofilin (Sigma) 1:500 AlexaFluor 488 chicken
anti-rabbit IgG (Invitrogen) 1:1000 or Rhodamine Red IgG
(Jackson ImmunoResearch) 1:100. Coverslips were mounted onto
glass slides using Prolong Gold+DAPI (Invitrogen) and sealed with
nail polish. Images were taken with 636or 1006objectives on a
Leica DMLB microscope equipped with a Diagnostic Instruments
Color Mosaic camera and software and analyzed using ImageJ
(NIH) or using the 406or 636objective and sequential scans of
the 405 nm, 488 nm, and 543 nm lasers as appropriate on a Zeiss
LSM 510 Meta confocal microscope at the Keck Center for
Microscopy at the University of Washington.
Migration and Invasion assays
The lower sides of the transwell inserts (Corning; 8 mm pores)
were coated with 100 mg/ml fibronectin overnight at 37uC.
Invasion assays were performed using a modified migration assay
[59]; for invasion assays, the upper chambers of the transwells
were coated with diluted matrigel (BD Biosciences). For both
migration and invasion assays, 4610
4 cells were plated in the
upper chamber in serum-free media atop wounded HDF in the
lower chamber and incubated for 20 hours. Invasion assays were
also performed using conditioned media from Panc-1 cells in the
lower chamber. For migration assays, cells in the upper chamber
were removed and inserts were fixed in ice cold methanol.
Transwells stained with crystal violet, and absorbance was
measured at 590 nm. For invasion assays, transwells were fixed
in ethanol, and mounted onto slides with Prolong Gold plus DAPI
(Invitrogen). The number of migrating cells was counted per field
and results were calculated as number of cells relative to empty
vector control. Each sample was run in triplicate and in multiple
experiments. Shown are representative images; graphs indicate
average of five random fields 6 SEM.
Three Dimensional Invasion Assays
Invasion assays were also performed using iuvo 3D-ICC slides
(Bellbrook Labs). On day 21, channels were filled with diluted
phenol red free matrigel (BD Biosciences) mixed with Texas Red
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complete media was added to the right side port and media with
5 ng/ml EGF was added to the left port. Slide was incubated at
37uC overnight. Flow sorted HDF cells transfected with GFP-
empty vector or WT palladin-GFP were labeled with
QTracker585 (Invitrogen) as per manufacturer’s instructions,
trypsinized, and counted with a hemacytometer. 3,250 cells were
loaded into the right side port and fresh media+EGF added to the
left side port. Slide was incubated at ,30u angle to allow for
attachment of cells to the channel. 24 hours later, Panc1 cells were
labeled with QTracker655 (Invitrogen) and 650 cells were added
to the right side port. Cells were grown for 3 days and media
changed daily. Images were taken using the Zeiss LSM 510 Meta
confocal microscope using the 106 or 206 objectives and
sequential scans with the 568 nm and 405 nm lasers. Images
were exported from LSM Browser and analyzed with ImageJ.
Invadopodia Assay
Coverslips were prepared as described previously [60] with
modifications. In brief, coverslips were coated with Texas Red
labeled gelatin prepared with FluoReporter kit (Molecular Probes)
as per manufacturer’s instructions. Gelatin was heated to 37uC,
filtered through a 0.45 mm filter and spread onto coverslips. Excess
gelatin was removed and coverslips were let stand at $60u angle
for 30 minutes. Coverslips were incubated with cold glutaralde-
hyde, quenched with sodium borohydride, washed with PBS,
sterilized with 70% ethanol, and incubated with serum-free media
and then wounding conditioned media prior to cell plating. 10
5
cells were plated onto coverslips and returned to 37uC for
18 hours. Coverslips were fixed and mounted onto slides as
described above. Each transfection was tested multiple times.
Shown are representative images.
RhoA activation assay
Flow sorted GFP-empty vector or GFP-palladin expressing
HDF cells were grown overnight on gelatin coated coverslips in
wounding media as described above. RhoA G-LISA assay
(Cytoskeleton) was performed as reported [61]. Shown is the
average of six wells 6 SD.
Scanning electron microscopy
Samples were grown on coverslips and fixed at 37uC in fresh
half strength Karnovsky’s fixative and then overnight at 4uC.
Specimens were rinsed with cacodylate buffer and post fixed with
osmium tetroxide. Specimens were rinsed with distilled water, en
bloc stained with 2% uranyl acetate for 45 minutes and
dehydrated through a graded series of ethanols. Samples were
critical point dried with a Samdri-PVT-3B CPD (Tousimis
Research), mounted on aluminum stubs, sputter coated with
gold-palladium (Polaron SEM Coating Unit, E 5100, Polaron
Instruments Inc) and examined with a JEOL JSM 6300F field
emission scanning electron microscope (JEOL, Tokyo, Japan) at
an accelerating voltage of 15 kV. Shown are representative
images.
Proteomics Sample preparation
2610
6 cells were plated atop a transwell filter (Corning; 3 mm
pores) over wounded HDF cells. Sixteen hours after plating,
protein lysates were prepared as described in cold RIPA buffer
[62]. Lysates from equivalent numbers of cells expressing empty
vector (SILAC labeled), or unlabeled WT or FX palladin were
combined, acetone precipitated, and resuspended in 50 mM
ammonium bicarbonate. The proteins were reduced with DTT,
blocked with iodoacetimide, and digested with trypsin overnight.
Samples were purified over a C18 column (Nest Group, Inc.),
dried in a speed vacuum and stored at 220uC until mass
spectrometric analysis.
Western blot analysis
Protein lysates from equivalent numbers of cells were separated
by SDS-PAGE and transferred to HybondP membrane using
semi-dry transfer. Blots were blocked with 16 Superblock for
1 hour at RT, and then incubated with primary antibody diluted
1:2000 in 0.56 Superblock overnight at 4uC. Blots were washed
and incubated with HRP-conjugated goat anti-mouse or donkey
anti-rabbit (Thermo) diluted 1:2000 in 0.56 Superblock for
1 hour at RT. Blots were washed and protein bands visualized
using the Storm Phosphoimager following incubation with ECL
Plus (GE Life Sciences).
Mass spectrometric analysis
The samples were analyzed using an LTQ-Orbitrap hybrid
mass spectrometer (Thermo Fisher Scientific) coupled with nano-
flow HPLC, which consists of a trap column (100 mm61.5 cm)
packed with Magic C18AQ resin (5 mm, 200 A ˚ particles;
Michrom Bioresources), followed by an analytical column
(75 mm627 cm) packed with Magic C18AQ resin (5 mm, 100 A ˚
particles; Michrom Bioresources). The peptide samples were
analyzed using a 90-minute non-linear gradient, starting at 5%
acetonitrile with 0.1% formic acid (against water with 0.1% formic
acid), changing to 7% over 2 minutes, then to 35% over
90 minutes with a flow rate at 300 nL/min. The mass spectrom-
etry experiment consisted of a full MS scan in the Orbitrap
followed by up to 5 MS/MS spectra acquisitions in the linear ion
trap using collision induced dissociation. An exclusion time of
45 sec was used to enhance the interrogation of low abundance
peptides.
Proteomics data processing
The MS/MS data was searched against IPI human protein
database using X!tandem algorithm. The assignment of peptide
sequence was validated using PeptideProphet. Peptides with a
probability score of 0.9 or above were selected for protein
identification using ProteinProphet. The quantitative ratio of
peptide/protein was calculated using Xpress software.
Supporting Information
Figure S1 Alpha actinin staining increases with pancre-
atic cancer progression. A) Strong alpha-actinin staining was
observed within the stromal compartment of pancreatic cancer
(right panel) sections but dramatically reduced in normal tissue (left
panel). Alpha-actinin is a binding partner of 90 kD palladin and is a
known invadopodia protein. B) Plot indicates the mean IHC score
6 SEM for normal pancreas (n=20) or cancer (n=21). Scoring
guidelines are outlined in Table S1.
(TIF)
Figure S2 Validation of up-regulated proteins identified
by proteomics of ‘‘feet’’ from palladin-activated fibro-
blasts. A) Invadopodia proteins: cofilin, cortactin, and profilin,
are confirmed to be up-regulated by immunofluorescence (IF) (top
left panel, top right panel and bottom right panel, respectively). Stem cell
marker, nestin, is also up-regulated (bottom left panel). Green=-
palladin or empty vector; red=antibody (cofilin, cortactin, nestin,
or profilin); blue=DAPI. B) Up-regulation of cortactin, profilin,
and cathepsin D in lysates prepared from ‘‘feet’’ of palladin-
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vector are demonstrated in the Western blot.
(TIF)
Table S1 Semi-quantitative scoring guidelines for im-
munohistochemical staining of pancreas tissue sections.
Shown are semi-quantitative scoring guidelines for immunohisto-
chemical staining of pancreas tissue sections. Results were scored
as diffuse or focal and were graded semi-quantitatively for intensity
of staining from 0=no staining to 4+=the most intense staining.
The tissues that were stained included pre-cancerous low and
high-grade dysplasia, cancer and normal pancreas. Scoring
systems for periductal or lesional stroma and parenchymal stroma
are presented. Parenchymal stroma designates stroma which is not
solely associated with a duct or lesion and includes intralobular
stroma between acini, as well as interlobular stroma and confluent
areas of fibrosis.
(DOC)
Table S2 Proteomics analysis of ‘‘feet’’ from palladin-
activated fibroblasts. Shown are the results of proteomics
analysis of pseudopodia. The IPI protein identifier, gene symbol,
description and ratios for fibroblasts transfected with wildtype
(WT) or Family X mutant (FX) palladin relative to empty vector
(EV). The total spectral counts reflect the number of peptides
identified. Samples with no ratio shown but one spectral count
reflect that the protein was present in the sample but could not be
quantified. If no spectral counts were shown, the protein was
absent or undetectable.
(DOC)
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